Lv1
10 积分 2024-08-20 加入
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
9小时前
待确认
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
[Expert consensus on diagnosis and treatment of lung cancer complicated with interstitial lung disease]
2个月前
已完结
Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis
3个月前
已完结
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
3个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
3个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
3个月前
已完结
Effect of JAK/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer
4个月前
已完结
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
6个月前
已完结
Characteristics of Extensive Stage Small Cell Lung Cancer: A National Cancer Database Review
6个月前
已关闭
皖公网安备34019202002308
